Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.49 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MPI | P34949 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3309675 | 0.91 | BRD4 (0.50) | BRD4OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL9770095 | 0.91 | BRD4 (0.50) | BRD4OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL3633908 | 0.89 | BRD4 (0.46) | BRD4OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL30684883 | 0.89 | BRD4 (0.48) | BRD4OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL9770000 | 0.87 | BRD4 (0.47) | BRD4OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL10427679 | 0.85 | BRD4 (0.43) | BRD4OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL10755656 | 0.85 | BRD4 (0.45) | BRD4OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL21142455 | 0.84 | BRD4 (0.68) | BRD4OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL16836131 | 0.84 | BRD4 (0.52) | BRD4OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL13259208 | 0.83 | OPRM1 (0.43) | BRD4OPRM1OPRD1OPRK1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345766-B2 | Tetrahydro-as-indacenyl catalyst composition, catalyst system, and processes for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3452520-B1 | TETRAHYDRO-AS-INDACENYL CATALYST COMPOSITION, CATALYST SYSTEM, AND PROCESSES FOR USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20210238319-A1 | Tetrahydro-as-indacenyl Catalyst Composition, Catalyst System, and Processes for Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2021-08-05 | — | — | US | disclosed |
| CN-109071700-B | Tetrahydroasymmetric indacenyl catalyst compositions, catalyst systems, and methods of use thereof | 埃克森美孚化学专利公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-3452520-A1 | TETRAHYDRO-AS-INDACENYL CATALYST COMPOSITION, CATALYST SYSTEM, AND PROCESSES FOR USE THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| US-20170320976-A1 | TETRAHYDRO-AS-INDACENYL CATALYST COMPOSITION, CATALYST SYSTEM, AND PROCESSES FOR USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. | 2017-11-09 | — | — | US | disclosed |
| WO-2017192225-A1 | TETRAHYDRO-AS-INDACENYL CATALYST COMPOSITION, CATALYST SYSTEM, AND PROCESSES FOR USE THEREOF | EXXONMOBIL CHEMICAL PATENTS, INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| US-9803037-B1 | Tetrahydro-as-indacenyl catalyst composition, catalyst system, and processes for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2017-10-31 | — | — | US | disclosed |
| EP-0745081-B1 | INDANE-2-MERCAPTOACETYLAMIDE DISULFIDE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE | MERRELL PHARMA INC (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-0656001-B1 | NOVEL 2-SUBSTITUTED INDANE-2-MERCAPTOACETYLAMIDE TRICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE | MERRELL PHARMA INC (US) | 1999-09-15 | — | — | EP | disclosed |
| US-5428158-A | 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0656001-A1 | NOVEL 2-SUBSTITUTED INDANE-2-MERCAPTOACETYLAMIDE TRICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE | MERRELL PHARMACEUTICALS INC. (US) | 1995-06-07 | — | — | EP | disclosed |
| US-5420271-A | Analgesics, cardiovascular disorders, diuretics or hypoaldosteronemic agents | MERRELL DOW PHARMACEUTICALS, INC. (US) | 1995-05-30 | — | — | US | disclosed |
| US-5407960-A | For cardiovascualr disorders, pain | SCHERING CORPORATION (US) | 1995-04-18 | — | — | US | disclosed |
| WO-1994004531-A1 | NOVEL 2-SUBSTITUTED INDANE-2-MERCAPTOACETYLAMIDE TRICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-03-03 | — | — | WO | disclosed |
| US-5252601-A | 2-mercaptomethylene-tetrahydronaphthalene and indane-2-carboxamide derivatives as enkephalinase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0534396-A2 | 2-Substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace | MERRELL PHARMACEUTICALS INC. (US) | 1993-03-31 | — | — | EP | disclosed |
| EP-0534363-A2 | Novel 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace | MERRELL PHARMACEUTICALS INC. (US) | 1993-03-31 | — | — | EP | disclosed |
| EP-0516980-A1 | Novel 2-mercaptomethylene-tetrahydronaphthalene and indane-2-carboxamide derivatives as enkephalinase inhibitors | MERRELL PHARMACEUTICALS INC. (US) | 1992-12-09 | — | — | EP | disclosed |
| WO-1991009840-A1 | MERCAPTOCYCLOACYL AMINOACID ENDOPEPTIDASE INHIBITORS | SCHERING CORPORATION (US) | 1991-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320976-A1 | TETRAHYDRO-AS-INDACENYL CATALYST COMPOSITION, CATALYST SYSTEM, AND PROCESSES FOR USE THEREOF | MLX, TXN, TSNAX | BRD4 2137/4885OPRM1 233/4885OPRD1 1905/4885 |
| US-20210238319-A1 | Tetrahydro-as-indacenyl Catalyst Composition, Catalyst System, and Processes for Use Thereof | MLX, TXN, TSNAX | BRD4 2748/4885OPRM1 208/4885OPRD1 2067/4885 |
| US-11345766-B2 | Tetrahydro-as-indacenyl catalyst composition, catalyst system, and processes for use thereof | MLX, TXN, TSNAX | BRD4 2748/4885OPRM1 208/4885OPRD1 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.